Robert W. Baird Has Lowered Expectations for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its target price reduced by Robert W. Baird from $200.00 to $150.00 in a report published on Tuesday morning, Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on the stock. Oppenheimer lowered their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday. Stephens increased their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Morgan Stanley lifted their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Needham & Company LLC cut their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $144.80.

TransMedics Group Stock Up 0.5 %

TransMedics Group stock opened at $82.40 on Tuesday. The firm has a market capitalization of $2.77 billion, a PE ratio of 87.66 and a beta of 1.99. The company’s 50-day moving average is $140.51 and its 200-day moving average is $139.29. TransMedics Group has a fifty-two week low of $38.13 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 8.48.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.12) EPS. Sell-side analysts anticipate that TransMedics Group will post 1.11 earnings per share for the current year.

Insider Activity

In related news, insider Anil P. Ranganath sold 4,289 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares in the company, valued at approximately $1,353,514.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the transaction, the insider now owns 8,893 shares in the company, valued at approximately $1,353,514.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 61,247 shares of company stock valued at $9,518,181 over the last three months. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of TMDX. Vanguard Group Inc. grew its holdings in shares of TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after buying an additional 50,673 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of TransMedics Group by 3.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock valued at $53,977,000 after purchasing an additional 21,737 shares during the last quarter. Oak Ridge Investments LLC raised its stake in shares of TransMedics Group by 59.5% during the 1st quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company’s stock worth $1,351,000 after buying an additional 6,813 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of TransMedics Group by 35.1% during the 1st quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company’s stock worth $1,286,000 after buying an additional 4,518 shares in the last quarter. Finally, Fidelis Capital Partners LLC acquired a new stake in shares of TransMedics Group in the 1st quarter worth approximately $35,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.